Emergent Biosolutions (EBS) Intrinsic Value Calculator

Updated: Nov 16, 2026

Emergent Biosolutions (EBS) trades at $5.79, below its base-case intrinsic value of $14.55 — an implied 151% margin of safety. The model starts from $1.05 in expected earnings per share, grows it at 25.0% annually (analyst consensus) decaying to a 4% terminal rate by Year 5, applies a 11.5x exit multiple, and discounts the result back at 10% per year. The discount suggests the market expects slower growth or a lower multiple than the base case; use the sliders below to stress-test how much growth deterioration the current price already absorbs.

Undervalued by 151.3%
Current Price
$5.79
Intrinsic Value
$14.55
Implied Upside: +151.3%

Discounted Cash Flow with Growth Decay Model

Customize Your Valuation

Adjust the assumptions below to model different scenarios. The intrinsic value updates in real-time.

Conservative
Base Case
Aggressive
Time Horizon 5 years
3 years 10 years
Initial Growth Rate 25.0%
0% (No Growth) 50% (High Growth)
Terminal Growth Rate 4.0%
0% (Decline) 6% (GDP+)
Discount Rate (Required Return) 10.0%
5% (Low Risk) 15% (High Risk)
Exit PE Multiple 11.5x
8x (Value) 40x (Growth)
Calculated Intrinsic Value
$14.55
--
Tradestie Long-Horizon Cycle Intelligence (2009–2025 • Split-Invariant)

Tradestie Long-Horizon Financial Resilience & Peer Growth Benchmark (17-Year Cycle Analysis)

Outside-View Peer Growth Benchmark Pharmaceutical Preparations • 2498+ US Equities Benchmarked

Across 19 years of multi-cycle financial history in Pharmaceutical Preparations, only 37.0% of peer companies at all-scale revenue scale (2020 historical 5-year windows; industry median CAGR: 7.6%/yr) sustained ≥15%/yr 5-year compound revenue growth (broad all-scale equity base rate: 26.2%).

≥5%/yr (5Y)
56.1%
All all-scale: 57.1%
≥10%/yr (5Y)
44.7%
All all-scale: 37.8%
≥15%/yr (5Y)
37.0%
All all-scale: 26.2%
≥20%/yr (5Y)
30.2%
All all-scale: 19.3%
≥25%/yr (5Y)
25.9%
All all-scale: 14.6%
≥30%/yr (5Y)
23.1%
All all-scale: 11.3%
Sector Revenue Pool (SPDR S&P Biotech ETF): Market-implied 5Y revenue CAGR for EBS is -10.7%/yr vs faded consensus anchor of 3.7%/yr (pool implied: 50.2%/yr).
17-Yr Revenue Scale
$235M → $743M
16Y CAGR: +7.5%/yr • 5Y: -13.7%
2008–2009 Cycle Trough Floor
17.1% Op Margin
FY2009 Rev: $235M
2022 Rate-Shock Floor
-69.2% Op Margin
FY2023 Rev: $1.05B (-6.1% YoY)
Latest vs Cycle Median Margin
13.5% vs 13.7% med
Cyclical Margin Profile — Stress-Test Exit Multiples
Multi-Cycle Revenue & Operating Margin Trajectory (2009–2025) Expansion 2008–09 / 2022 Macro Stress
17%
'09
26%
'10
12%
'11
11%
'12
14%
'13
20%
'14
27%
'15
22%
'16
22%
'17
12%
'18
10%
'19
28%
'20
19%
'21
-15%
'22
-69%
'23
-10%
'24
14%
'25
Inspect All 17 Fiscal Years of Annual Revenue & Operating Margin History Toggle Annual Ledger ↓
Fiscal Year Annual Revenue YoY Growth Operating Income Operating Margin Macro Cycle Regime
FY2025 (2025-12) $743M -28.8% $100M 13.5% Standard
FY2024 (2024-12) $1.04B -0.5% -$109M -10.4% Standard
FY2023 (2023-12) $1.05B -6.1% -$726M -69.2% 2022–23 Shock Floor
FY2022 (2022-12) $1.12B -37.0% -$170M -15.2% 2022 Rate Shock
FY2021 (2021-12) $1.77B +14.0% $341M 19.2% Standard
FY2020 (2020-12) $1.56B +40.6% $438M 28.2% Standard
FY2019 (2019-12) $1.11B +41.4% $114M 10.3% Standard
FY2018 (2018-12) $782M +39.5% $90M 11.5% Standard
FY2017 (2017-12) $561M +14.8% $124M 22.2% Standard
FY2016 (2016-12) $489M -6.5% $106M 21.6% Standard
FY2015 (2015-12) $523M +16.1% $142M 27.1% Standard
FY2014 (2014-12) $450M +43.9% $89M 19.8% Standard
FY2013 (2013-12) $313M +10.9% $43M 13.7% Standard
FY2012 (2012-12) $282M +3.1% $30M 10.6% Standard
FY2011 (2011-12) $273M -4.5% $32M 11.7% Standard
FY2010 (2010-12) $286M +21.9% $74M 25.7% Standard
FY2009 (2009-12) $235M — $40M 17.1% 2008–09 Trough Floor

Year-by-Year Projections

EPS growth decays from initial rate to terminal rate over the projection period.

Year Growth Rate EPS Stock Price Present Value

Price Projection

Sensitivity Analysis

How intrinsic value changes with different growth and discount rate assumptions.

Model Inputs
Base EPS $1.05
Current Price $5.79
Historical PE 11.5x
Analyst Growth Est. 25.0%
How It Works

Growth Decay Model: We project EPS growth that gradually slows from the initial rate to a terminal rate (typically 3-4%, matching long-term GDP growth).

Terminal Value: At the end of the projection period, we apply an exit PE multiple to estimate the future stock price.

Discounting: Future values are discounted back to today using your required rate of return (discount rate).